Kedokteran & Kesehatan editorial
Open AccessOA2023
Long-Term Results of Organ Preservation in Patients with Rectal Adenocarcinoma Treated with Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial
In the OPRA trial, total neoadjuvant therapy achieved 5-year disease-free survival of 71% and 69% for induction chemotherapy followed by chemoradiation (INCT-CRT) and chemoradiation followed by consolidation chemotherapy (CRT-CNCT), respectively. TME-free survival was significantly higher with CRT-CNCT (54% vs 39%), and 94% of tumor regrowth occurred within 2 years.
F. Verheij; D. Omer; H. Williams; Sabrina T. Lin; L. Qin; J. Buckley; Hannah M. Thompson; J. Yuval; Jin K. Kim; R. Dunne; J. Marcet; P. Cataldo; B. Polite; Daniel O. Herzig; D. Liska; S. Oommen; Charles M. Friel; C. Ternent; A. Coveler; Steven R. Hunt; A. Gregory; M. Varma; Brian L. Bello; Joseph C. Carmichael; J. Krauss; A. Gleisner; José G. Guillem; Larissa K. F. Temple; K. Goodman; N. Segal; A. Cercek; R. Yaeger; G. Nash; M. Widmar; Iris H. Wei; E. Pappou; M. Weiser; P. Paty; J. Smith; Abraham J. Wu; M. Gollub; L. Saltz; J. García-Aguilar· Journal of Clinical Oncology· 2023· DOI 10.1200/JCO.23.01208
The core problem
The OPRA trial (ClinicalTrials.gov identifier: NCT02008656) is a randomized phase II study that evaluated total neoadjuvant therapy (TNT) for organ preservation in patients with stage II/III rectal adenocarcinoma. The initial report demonstrated feasibility of a watch-and-wait (WW) approach in patients achieving a complete or near-complete response after TNT. Here, we present long-term results on organ preservation rate and oncologic outcomes after a median follow-up of 5.1 years. The primary end point was disease-free survival (DFS); the secondary end point was TME-free survival (i.e., avoidance of total mesorectal excision).
Innovation
Patients with stage II/III rectal cancer were randomly assigned to receive either induction chemotherapy followed by chemoradiation (INCT-CRT) or chemoradiation followed by consolidation chemotherapy (CRT-CNCT). After completion of TNT, patients were restaged; those with a complete or near-complete response were offered watch-and-wait (WW), while those with an incomplete response were recommended to undergo total mesorectal excision (TME). A total of 324 patients were enrolled (INCT-CRT, n = 158; CRT-CNCT, n = 166). The primary end point was DFS, and the secondary end point was TME-free survival. Survival curves were estimated using the Kaplan-Meier method and compared with the log-rank test.
Introduction
The OPRA trial (ClinicalTrials.gov identifier: NCT02008656) is a randomized phase II study that evaluated total neoadjuvant therapy (TNT) for organ preservation in patients with stage II/III rectal adenocarcinoma. The initial report demonstrated feasibility of a watch-and-wait (WW) approach in patients achieving a complete or near-complete response after TNT. Here, we present long-term results on organ preservation rate and oncologic outcomes after a median follow-up of 5.1 years. The primary end point was disease-free survival (DFS); the secondary end point was TME-free survival (i.e., avoidance of total mesorectal excision).
Why it matters
The updated OPRA results confirm that long-term organ preservation is achievable in approximately half of patients with rectal cancer treated with TNT. The CRT-CNCT sequence yielded a higher TME-free survival rate, suggesting that consolidation chemotherapy after chemoradiation may improve organ preservation. Importantly, the majority of tumor regrowths occurred within the first 2 years, supporting intensive surveillance during this period. The similar DFS between patients who underwent TME after restaging and those who had TME after regrowth indicates that a watch-and-wait approach with salvage surgery does not compromise oncologic outcomes. These findings reinforce WW as a viable option for selected patients achieving a complete or near-complete response to TNT.
Who should read this
Pembaca Research Digest dan praktisi rumpun ini.
Opening member content…